Delving into the Latest Updates on Ivermectin with Synapse

Overview

Basic Info

SummaryIvermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity. The drug was granted approval by the FDA in November 1996, and its development can be attributed to the remarkable efforts of Merck Sharp & Dohme Corp. Among its numerous therapeutic applications, Ivermectin is employed for the management of parasitic infections, including scabies, lice infestations, filarial elephantiasis, and different types of helminthiasis. Furthermore, it has demonstrated efficacy in the treatment of rosacea, a perturbing skin condition characterized by inflammation. Ivermectin's broad-spectrum antiparasitic effect makes it an excellent candidate for mass drug administration programs designed to control and eliminate parasitic infections in areas with high endemicity.

Drug Type

Small molecule drug

Synonyms

mdc-STM, CD-5024, K-237

+ [13]

Target

GluCls

Action

modulators

Mechanism

Glutamate-gated chloride channel modulators

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

RosaceaLice InfestationsScabies+ [9]

Inactive Indication

Acne VulgarisDermatitis, AtopicPediculus capitis infestation

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Zhejiang Hisun Pharmaceutical Co., Ltd.

MedinCell SAMerck Sharp & Dohme (Australia) Pty Ltd.

+ [7]

Inactive Organization

Galderma Research & Development SNC

Galderma Holding SATeva Pharmaceuticals USA, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (22 Nov 1996),

OnchocerciasisStrongyloidiasis

RegulationOrphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS Registry70209-81-3

This is a clinical trial to compare two formulations of the drug ivermectin: the standard 3mg tablet formulation versus a newly developed infant formula preparation. The goal of the trial is to determine if the new formulation functions in the same way, tastes the same and causes no new side effects. The trial will involve 52 participants who will be healthy adult volunteers. The participants will receive both formulations - the order they receive each formulation will be assigned randomly (similar to the toss of a coin).

Start Date01 Aug 2025

Sponsor / Collaborator

Murdoch Childrens Research Institute

[+1]

NCT05500326

/ Not yet recruitingPhase 2

Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)

This is an open label prospective pharmacokinetic single arm study in Laos PDR. This study will be embedded within a cluster-randomized controlled trial of interventions to address childhood undernutrition (SUANHOAM Trial, ACTRN12620000520932) and involves a collaboration with the Murdoch Children's Research Institute, Burnet institute and Lao Tropical and Public Health Institute.
ITCHY Study:
The primary objective is to determine in young children aged 2 to <5 years and weighing 10 to <15 kg if an ivermectin dose of 3 mg achieves comparable drug exposures to the recommended dose in older children. It aims to provide reliable evidence for a safe and effective dose of ivermectin in young children who are especially vulnerable to scabies infections and the associated secondary complications.
ITCHY2 Study:
An embedded phase 2 multicentre, open label prospective pharmacokinetic study in Laos PDR of ITCHY Study. The primary objective is to determine the plasma ivermectin drug exposure in children aged 3 months to 2 years and weighing ≥2 kg receiving an age specific ivermectin dose.

Start Date01 Apr 2025

Sponsor / Collaborator

Murdoch Childrens Research Institute

[+1]

100 Clinical Results associated with Ivermectin

Login to view more data

100 Translational Medicine associated with Ivermectin

Login to view more data

100 Patents (Medical) associated with Ivermectin

Login to view more data

8,150

Literatures (Medical) associated with Ivermectin

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

Article

Author: Augustin, M. ; Wagner, J. N. ; Zirkenbach, F. ; Grote, C.

PURPOSE:

Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.

MATERIAL AND METHODS:

This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis. At first, dupilumab was continued alongside doxycycline, metronidazole gel and ivermectin cream.

RESULTS:

Following a worsening of her skin condition, dupilumab was discontinued. Lebrikizumab was introduced, leading to significant regression of the lesions.

CONCLUSIONS:

This case highlights a rare paradoxical skin reaction to dupilumab, potentially linked to the blockade of IL-4Rα, which may shift the immune response towards a Th1/Th17 phenotype. The findings suggest that alternative therapies, such as IL-13 inhibitors, should be considered when cutaneous side effects arise during dupilumab treatment.

01 Oct 2025·PARASITOLOGY INTERNATIONAL

Comparison of prevalence and strongyle egg counts per gram of feces in horses at pasture and in stables following ivermectin/praziquantel treatment

Article

Author: Forbes, Eliot ; Kim, Byung-Sun ; Ryu, Seung-Ho ; An, Sung-Jun ; Choe, Seongjun

Equine strongyle infections are prevalent among grazing horses worldwide, yet research on anthelmintic efficacy and parasite management strategies in South Korea remains limited. This study investigated the infection dynamics and parasite burden in horses managed under different systems (pasture vs. stable) over a one-year period in Jeju, South Korea, assessing the impact of management practices on parasite burden and the effectiveness of current deworming regimens. Thirty-two horses were administered ivermectin/praziquantel in June 2022 and assigned to either pasture (n = 16) or stable (n = 16) groups. Each group was further divided based on deworming intervals (3-6-3 months vs. 9-3 months). Monthly egg per gram (EPG) counts of strongyle eggs were conducted to evaluate seasonal variations in parasite burden. Results indicated that stabled horses maintained near-zero EPG levels year-round, whereas pasture-managed horses exhibited significant seasonal fluctuations, with EPG values peaking in summer and autumn before declining in spring. Deworming intervals had minimal impact on parasite burden in stabled horses. However, pasture horses showed varying reinfection risks, with the highest EPG value increase occurring in summer. These findings suggest that routine three-month deworming may be excessive for stabled horses but adequate for pasture-managed horses due to higher reinfection rates. Instead, targeted selective treatment based on EPG monitoring is recommended as a more effective and sustainable parasite control strategy to optimize deworming regimens and mitigate anthelmintic resistance.

01 Aug 2025·TISSUE & CELL

Targeting EGFR/PI3K/AKT/mTOR and Bax/Bcl-2/caspase3 pathways with ivermectin mediates its anticancer effects against urethane-induced non-small cell lung cancer in BALB/c mice

Article

Author: Malak, Marina N ; Arafa, Elshaimaa A ; Khalaf, Marwa M ; Arab, Hany H ; Hamzawy, Mohamed A ; Abdel-Fattah, Maha M

Lung cancer's mortality is among the highest compared to other cancers globally. However, a recent study has shown that ivermectin, an antiparasitic drug, may have a promising anticancer effect on lung cancer. The present study aimed to investigate the impact of ivermectin on EGFR.³/PI3K⁴/AKT⁵^/mTOR⁶ signaling pathway in NSCLC.⁷ Mice were divided into four groups; (1) normal; (2) oral ivermectin alone (5 mg/kg) daily; (3) NSCLC was induced by urethane (1.5 g/kg, i.p.) at days one and sixty; (4) NSCLC group treated with ivermectin. The effect of ivermectin on macroscopic, microscopic, and lung index was assessed. The antitumor and antiproliferative effects of ivermectin were investigated by CYFRA 21-1 level and Ki-67, respectively. IHC determined the molecular expression of EGFR⁸, while phosphorylated PI3K, AKT, and mTOR were quantified by Western blotting assay. ELISA assay of active caspase 3, Bcl-2⁹, and BAX¹⁰ was used to assess the apoptotic effect of ivermectin. Finally, VEGF¹¹ lung content was measured. Findings showed that ivermectin improved macro and microscopic pathological changes. Ivermectin induced cytotoxic effect as indicated by CYFRA 21-1 suppression besides enhancing BAX/Bcl-2 ratio and active caspase 3. The immunoexpression of Ki-67 and EGFR declined. Ivermectin remarkably reduced p-PI3K, p-AKT, p-mTOR, and VEGF expressions. Overall, the study proposes ivermectin as a promising drug for lung cancer through its orchestral regulation of EGFR/PI3K/AKT/mTOR/VEGF signaling.

97

News (Medical) associated with Ivermectin

28 Mar 2025

·www.drugs.com

Measles Outbreak Leads to Dangerous Vitamin A Toxicity

FRIDAY, March 28, 2025 -- As a measles outbreak spreads across U.S., doctors are now seeing a new and unexpected danger: Children getting sick from taking too much vitamin A. At Covenant Children’s Hospital in Lubbock, Texas, several unvaccinated children showed signs of liver problems after taking large amounts of vitamin A, according to Dr. Lara Johnson , the hospital’s chief medical officer. U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr . has promoted vitamin A during the outbreak, even suggesting it might help prevent measles . But doctors say this isn’t true. “If people have the mistaken impression that you have an either-or choice of MMR vaccine or vitamin A, you’re going to get a lot of kids unnecessarily infected with measles. That’s a problem, especially during an epidemic,” Dr. Peter Hotez , co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, told CNN . “And second, you have this unregulated medicine in terms of doses being given and potential toxicities.” The measles, mumps and rubella (MMR) vaccine is the only proven way to prevent measles. It is 97% effective after two doses. Kennedy has said he encourages vaccines, but considers vaccination a personal choice. Vitamin A can be helpful for people with measles when given in the right dose by a doctor. But taking too much, especially without medical supervision, can be dangerous. Vitamin A is fat-soluble and can build up in the body. This can lead to dry skin, blurry vision, bone problems and liver damage. In pregnant women, it can even cause birth defects. Dr. Lesley Motheral , a pediatrician in Lubbock, said kids in Texas are generally well-nourished and don’t need extra vitamin A. “Recovery for patients with acute toxicity can be rapid when the vitamin is discontinued,” Motheral said. “Sadly, some of the more serious problems with vitamin A toxicity are not always reversible.” The Council for Responsible Nutrition (CRN), a group representing supplement makers, also warned parents not to give their children high doses of vitamin A. “While vitamin A plays an important role in supporting overall immune function, research hasn’t established its effectiveness in preventing measles infection. CRN is concerned about reports of high-dose vitamin A being used inappropriately, especially in children,” it said in a statement . Johnson said some parents may be following questionable advice from social media or health influencers. “It’s coming out of the health and wellness … influencer industry that downplays the importance of vaccines and tries to promote various spectacular cures like ivermectin or hydroxychloroquine or vitamin A,” Hotez added. In a recent interview with Fox News , Kennedy promoted a treatment plan that includes vitamin A, a steroid, an antibiotic and cod liver oil, but doctors say there’s little to no proof this works for measles. The measles outbreak has now affected at least 378 people in 17 states, from Texas and New Mexico to Vermont, New York and Washington. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Vaccine

18 Feb 2025

·www.prnewswire.com

Independent Medical Alliance Publishes Inaugural Issue of the Journal of Independent Medicine

Journal Represents a New Era of Unbiased Medical Research WASHINGTON, Feb. 18, 2025 /PRNewswire/ -- Today, the Independent Medical Alliance (IMA), formerly FLCCC, proudly announces the Journal of Independent Medicine, a groundbreaking peer-reviewed publication dedicated to restoring integrity, transparency, and scientific independence in medical research and education. Continue Reading Journal of Independent Medicine Cover The Journal of Independent Medicine is designed to challenge industry influence, prioritize ethical scientific inquiry, and provide a critical platform for research that mainstream medical journals often ignore or suppress. This includes studies on repurposed medicines, alternative and integrative therapies, medical ethics, constitutional rights in healthcare, and the ongoing implications of COVID-19 and other healthcare policies. A Platform for Honest, Transparent Science Medical research today is increasingly driven by pharmaceutical industry funding, which introduces significant bias in clinical studies and publication decisions. The Journal of Independent Medicine seeks to counteract this trend by: Eliminating Big Pharma Influence – The journal does not accept funding from pharmaceutical companies, ensuring that research is evaluated on scientific merit alone. Encouraging Full Transparency – All authors must disclose conflicts of interest, and submitted research will undergo rigorous, ethical peer review. In addition, for original investigations, the full original data must be available to the reviewers and editors. Championing Underreported Topics – The journal provides a home for controversial and underfunded research, including studies on repurposed medicines, Traditional Chinese Medicine, and non-pharmaceutical interventions. Publishing Negative and Inconclusive Findings – Unlike mainstream journals, which often reject studies that do not show a drug's effectiveness, the Journal of Independent Medicine acknowledges the scientific value of negative results. "Our goal is simple but profound—restore trust in medical research by publishing truthful, high-quality science that is free from corporate and political influence," said Dr. Joseph Varon, Editor-in-Chief of the Journal of Independent Medicine. "This journal will be a sanctuary for researchers and clinicians who want to engage in Honest Medicine and publish findings that can truly help patients, rather than serve financial interests." Dr. Varon further emphasized the journal's global reach and expertise, stating, "With 43 esteemed editorial board members representing 17 different countries, the Journal of Independent Medicine is built on a foundation of diverse perspectives and international collaboration. Each paper undergoes a rigorous double-blind peer review process by our editorial board members, ensuring that research is evaluated solely on its scientific merit, free from bias or external influence." First Issue: February 18, 2025 The inaugural issue of the Journal of Independent Medicine will be offered at no cost on the journal's website () and feature research articles, reviews, and critical discussions on topics including: The hidden mental health crisis among doctors Honest Medicine™ – Reclaiming scientific integrity in medical research COVID-19 patient outcomes retrospective study Traditional Chinese Medicine (Part 1 in a series) Ivermectin and its evolving role in therapeutic medicine Repurposed Medicine – Exploring cost-effective, evidence-based drug repurposing Constitutional Rights in the COVID-19 Era Disparities in access to healthcare Translational fidelity in mRNA vaccines About the Journal of Independent Medicine The Journal of Independent Medicine, published by the Independent Medical Alliance™ (IMA), is a quarterly peer-reviewed, multi-specialty journal dedicated to advancing unbiased medical research. The IMA is a nonprofit, 501(c)(3) organization and coalition of physicians, scientists, and other healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through the empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA drives a movement to create a more compassionate and effective healthcare system. For more information about the Journal of Independent Medicine, visit . For more information about the Independent Medical Alliance, visit Media Contact Lynne Kristensen [email protected] SOURCE Independent Medical Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

16 Jan 2025

·www.prnewswire.com

Frontline COVID Docs (FLCCC) Gear Up for Kennedy Confirmation Battle; Announce New Name & Expanded Focus

"For many of us, COVID was an eye-opener. The shameful censorship of discussion and debate among accomplished doctors by America's healthcare agencies cost many lives. This must never happen again." – Dr. Joseph Varon WASHINGTON, Jan. 16, 2025 /PRNewswire/ -- The Frontline COVID-19 Critical Care Alliance (FLCCC) announced today that the group is changing its name to the Independent Medical Alliance (IMA) as the nation prepares for the coming Kennedy nomination debates. "We're about to have an unprecedented national discussion about America's broken healthcare system," said Dr. Joseph Varon, President and Chief Medical Officer of the Independent Medical Alliance. "For many of us, COVID was an eye-opener. I was on the front lines fighting to save lives. The shameful censorship of discussion and debate among accomplished doctors by America's healthcare agencies cost many lives. This must never happen again." Representing over 15,000 doctors and other medical professionals, the FLCCC vaulted to national prominence by pushing back against vaccine mandates and other government induced COVID policy failures, while also advocating for early and cost-effective alternative treatments, including ivermectin, which has proven to be highly effective against COVID. "They demonized accomplished virologists and others who knew that ivermectin was saving lives," continued Varon. "Hundreds of thousands died due to the censorship of debate. At our hospital, we considered alternatives, and our published mortality rate was 4.4% while major hospitals at the time were experiencing 23% to 26% rates of ICU death." "Our success raised interest among those at FDA and CDC, but not the way one would expect. They sent scores of briefcase wielding bureaucrats to try and shut down our treatment programs. We were outside of the PhRMA profit orthodoxy. We were non-conformists. And although we were saving more lives, that didn't appear to be the priority." "The Kennedy confirmations will be about restoring health to America's healthcare systems, and we're looking forward to that discussion," concluded Varon. About the IMA (Formerly FLCCC Alliance) The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system. For more information about the Independent Medical Alliance, visit Contact Lynne Kristensen Independent Medical Alliance [email protected] (202) 987-5655 SOURCE Independent Medical Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AHA

100 Deals associated with Ivermectin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00804	Ivermectin	D11AX22 P02CF01	DB00602

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rosacea	United States	Galderma Laboratories LP	19 Dec 2014
Lice Infestations	United States	Arbor Pharmaceuticals LLC	07 Feb 2012
Scabies	Japan	MSD KK	21 Aug 2006
Ascariasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Elephantiasis, Filarial	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Enterobiasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Helminthiasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Hookworm Infections	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Trichuriasis	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Onchocerciasis	United States	Merck Sharp & Dohme Corp.	22 Nov 1996
Strongyloidiasis	United States	Merck Sharp & Dohme Corp.	22 Nov 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	Bulgaria	MedinCell SA	25 Mar 2022
Dermatitis, Atopic	Phase 2	Canada	Galderma Holding SA	01 Nov 2016
Dermatitis, Atopic	Phase 2	Canada	Galderma Research & Development SNC	01 Nov 2016
Acne Vulgaris	Phase 2	Canada	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Phase 2	Canada	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Phase 2	France	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Phase 2	France	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Phase 2	Germany	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Phase 2	Germany	Galderma Research & Development SNC	25 Apr 2016
Pediculus capitis infestation	Phase 1	United States	Taro Pharmaceuticals U.S.A., Inc.	20 Mar 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04966702 (Pubmed \| Infect Dis Poverty)	Phase 3	-	-	Ivermectin MDA	qfplowaegl(dzwicbluqi) = 11% vgeilxijlf (gcgdzyuoxh )	Positive	27 Mar 2025
NCT05305560 (SAIVE, CTgov)	Phase 2	COVID-19	400	Ivermectin Tablets (Active IMP)	gvluigkcnq = hzarkaglox ymhguhdwlp (nopsyyspjj, ogrpwogtpy - xekeamknvy) View more	-	10 Dec 2024
				Matching placebo tablets (Placebo)	gvluigkcnq = tsywpwcmnp ymhguhdwlp (nopsyyspjj, fyhsggenzw - nobdrjiend) View more
NCT03527732 (CTgov)	Phase 2/3	Trichuriasis	1,673	Albendazole (Albendazole in Côte d'Ivoire)	cobcqklons(kltyeoohhg) = igxpoyshgf egaqniroyn (vixdgxsckj, akuietezig - ebokgubmeb) View more	-	20 Mar 2024
				Albendazole+Ivermectin (Albendazole and Ivermectin in Côte d'Ivoire)	cobcqklons(kltyeoohhg) = vgpogbyboh egaqniroyn (vixdgxsckj, aohngsdmhf - uchbauksdd) View more
NCT04848688 (StrongMoxi_KH, CTgov)	Phase 3	Strongyloidiasis	332	Placebo+Moxidectin 2 mg (Moxidectin)	neaybjopmr = onfxbhegny wzqvosnkla (hltcvjlqpp, ozmgcncben - ydgzosxyop) View more	-	24 Jan 2024
				Placebo+Ivermectin 3 mg (Ivermectin)	neaybjopmr = ujhwzpnlkr wzqvosnkla (hltcvjlqpp, mceoczkafp - fzgkiwpfyh) View more
NCT03967054 (RIMDAMAL II, CTgov)	Phase 3	Malaria	4,124	Ivermectin (Ivermectin Mass Drug Administration)	njszuklmox(qfzkvdepxt) = vcmqurtjdz earunklzdc (guoneumxuy, bpzsduyrep - omatzvicjg) View more	-	11 Jan 2024
				Placebo oral tablet (Placebo Mass Administration)	njszuklmox(qfzkvdepxt) = bsiezjdqnn earunklzdc (guoneumxuy, cgmeertcbc - bswhdbfluf) View more
NCT05894538 (CTgov)	Phase 3	COVID-19	1,459	Ivermectin (Arm D - Ivermectin 600)	wraofuaagf(zptysujqod) = zmiwkcmwpc cvjkiuzzwn (xaupssxprg, ekyzeudygp - nsdxvqsvjc) View more	-	28 Sep 2023
				Placebo (Arm D - Placebo)	wraofuaagf(zptysujqod) = olupskytrq cvjkiuzzwn (xaupssxprg, kqojpgqmix - tzrqnlpthj) View more
NCT04510194 (COVID-OUT, CTgov)	Phase 3	COVID-19	1,323	Metformin (Treatment Arm - Metformin Only Group)	kkrhgnlawz = xplhrsosdb bexgkzhyij (lddptdxvra, vabnxdzaxu - snytgjldtw) View more	-	13 Jul 2023
				Placebo (Treatment Arm - Placebo Group)	kkrhgnlawz = aylxqasxra bexgkzhyij (lddptdxvra, yzyhotshai - bncboukhlr) View more
WCD2023	Not Applicable	Scabies	-	ivermectin (Community residents)	zvzbeyjtfn(gvboxblqaa) = rqhnwzczdg zlaawdduia (swgpkdigrr )	-	06 Jul 2023
WCD2023	Not Applicable	Rosacea	-	Ivermectin 1% cream and doxycycline 40 mg	dbhxnjzuyv(azhdpitbbo) = nftzgakslg ufcvmhrgww (ztigtmxyzl )	-	03 Jul 2023
				Ivermectin 1% cream and Placebo	dbhxnjzuyv(azhdpitbbo) = vfdsnbivoh ufcvmhrgww (ztigtmxyzl )
NCT04188301 (DOLF IDA/Oncho, CTgov)	Phase 2	Onchocerciasis	154	Albendazole+Ivermectin (IVM + ALB)	jezqluvuni = todabrcrfk weujirjzcm (vssecirygl, pilhrndebx - imimsqzsxr) View more	-	10 May 2023
				albendazole+ivermectin+diethylcarbamazine (IDA x 1 Dose)	jezqluvuni = vdmggnmjof weujirjzcm (vssecirygl, tagxvfnmlx - hhaykoorgg) View more